financetom
Business
financetom
/
Business
/
What's Going On With Lockheed Martin Shares After Scoring $4B Defense Order?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Lockheed Martin Shares After Scoring $4B Defense Order?
Apr 12, 2024 6:36 AM

Lockheed Martin Corporation ( LMT ) received a contract worth $4.10 billion from the Missile Defense Agency.

Aiming to enhance global interoperability, this contract will accelerate innovation and continue leading the development of the Command and Control, Battle Management and Communications (C2BMC) system, Lockheed Martin ( LMT ) said in a press release.

According to Benzinga Pro, LMT stock has lost over 7% in the past year. Investors can gain exposure to the stock via IShares U.S. Aerospace & Defense ETF and First Trust Exchange-Traded Fund First Trust Indxx Aerospace & Defense ETF .

The latest contract’s ordering period is from May 1, 2024, through April 30, 2029, with an option to extend through April 30, 2034.

Under the new C2BMC-Next scope, the system will be upgraded with the latest 21st Century Security technology for faster, multi-domain coordinated responses to emerging threats. 

The Lockheed Martin ( LMT ) team will primarily perform this work out of a new Huntsville, Alabama facility and Colorado Springs, Colorado locations.

Read Next: What’s Going On With Wells Fargo Shares After Beating Q1 Earnings?

“With C2BMC’s already well-established lines of reliable communication – operating 24/7, 365 days a year in more than 30 locations across the world – the ability to securely collaborate with other countries, across multiple domains, from any location in near real-time will be a game changer for the defense industry,” said Erika Marshall, Lockheed Martin C4ISR Vice President.  

Price Action: LMT shares are trading higher by 0.42% premarket to $454.22 on the last check Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ford to recall over 254,600 U.S. vehicles over issues with assistance features, NHTSA says
Ford to recall over 254,600 U.S. vehicles over issues with assistance features, NHTSA says
Mar 24, 2026
March 24 (Reuters) - Ford Motor ( F ) is recalling 254,640 vehicles in the U.S. over issues that may result in the loss of rearview camera image and some advanced driver assistance features, the U.S. National Highway Traffic Safety Administration said on Tuesday. ...
Autoliv to Launch Motorcycle Airbag Vest With RS Taichi
Autoliv to Launch Motorcycle Airbag Vest With RS Taichi
Mar 24, 2026
03:33 AM EDT, 03/24/2026 (MT Newswires) -- Autoliv ( ALV ) said Tuesday it will bring to market its first complete wearable protection for motorcycle riders, a vest with an integrated airbag system designed to reduce the risk of critical injuries in the event of a crash, in collaboration with RS Taichi. The company said the new product, integrated into...
SK Hynix may raise up to $10 billion from US listing, Korea Economic Daily says
SK Hynix may raise up to $10 billion from US listing, Korea Economic Daily says
Mar 24, 2026
SEOUL, March 24 (Reuters) - South Korea's SK Hynix is considering raising 10 trillion to 15 trillion won ($10.03 billion) through a potential U.S. listing, aiming to expand production capacity for advanced memory chips, the Korea Economic Daily reported. A U.S. listing would give the Nvidia ( NVDA ) supplier access to a wider pool of capital and could help...
Regeneron, Sanofi's Dupixent Approved in Japan as Bullous Pemphigoid Treatment
Regeneron, Sanofi's Dupixent Approved in Japan as Bullous Pemphigoid Treatment
Mar 24, 2026
03:13 AM EDT, 03/24/2026 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Tuesday the Ministry of Health, Labor and Welfare in Japan approved Dupixent, or dupilumab, as treatment for moderate-to-severe bullous pemphigoid, a rare skin disease. The approval was based on data from a phase 2/3 trial that showed over four times more patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved